Related references
Note: Only part of the references are listed.Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia An Effective but Myelosuppressive Regimen to Be Offered to Patients With Advanced Disease
Alessandra Tedeschi et al.
CANCER (2012)
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia
Steven P. Treon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau et al.
LANCET ONCOLOGY (2011)
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia
Irene M. Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia
Aldo M. Roccaro et al.
BLOOD (2010)
Regression modeling of competing risk using R: an in depth guide for clinicians
L. Scrucca et al.
BONE MARROW TRANSPLANTATION (2010)
International prognostic scoring system for Waldenstrom macroglobulinemia
Pierre Morel et al.
BLOOD (2009)
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
C. Buske et al.
LEUKEMIA (2009)
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma
Lapo Alinari et al.
MABS (2009)
Targeting NF-κB in Waldenstrom macroglobulinemia
Xavier Leleu et al.
BLOOD (2008)
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia
Aldo M. Roccaro et al.
BLOOD (2008)
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo
M. Wang et al.
LEUKEMIA (2008)
Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma
Patrizia Zappasodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide
Meletios Athanasios Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
Christine I. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: Results of WMCTG trial 03-248
Steven P. Treon et al.
CLINICAL CANCER RESEARCH (2007)
Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: A questionnaire-based report from the lung injury by bortezomib Joint Committee of the Japanese Society of Hematology and the Japanese Society of clinical Hematology
Akihiko Gotoh et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Dexamethasone reduces the risk of bortezomib-induced pulmonary complications in Japanese myeloma patients
Chihiro Shimazaki et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma
S Miyakoshi et al.
BLOOD (2006)
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia
Eva Kimby et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia
MA Dimopoulos et al.
CLINICAL LYMPHOMA (2005)
Diagnosis and management of Waldenstrom's macroglobulinemia
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): An eastern cooperative oncology group study (E3A98)
MA Gertz et al.
LEUKEMIA & LYMPHOMA (2004)
Treatment of Waldenstrom's macroglobulinemia with rituximab: Prognostic factors for response and progression
MA Dimopoulos et al.
LEUKEMIA & LYMPHOMA (2004)
Initial immunoglobulin M 'Flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia an eastern cooperative oncology group study
IM Ghobrial et al.
CANCER (2004)
Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia
SP Treon et al.
ANNALS OF ONCOLOGY (2004)
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RG Owen et al.
SEMINARS IN ONCOLOGY (2003)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia
MA Dimopoulos et al.
CLINICAL LYMPHOMA (2002)
Treatment of Waldenstrom's macroglobulinemia with rituximab
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
